HikariQ Health, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HikariQ Health, Inc. - overview
Established
2021
Location
Tokyo, -, Japan
Primary Industry
Biotechnology
About
Founded in 2021 and based in Tokyo, Japan, HikariQ Health, Inc. develops an antibody with a structure that enables the encapsulation of chemicals by changing antibody genes. As of January 2023, Kosuke Yoshii serves as the CEO of the company. In January 2023, HikariQ Health, Inc.
raised JPY 65 million in seed funding from Business Creation Capital, Coral Capital, and the UT Founder's Association. The company develops original immunoassay methods and antibody drugs using its unique antibody technology. The firm provides Q-body, an antibody modification technology that adds a sensor function without impairing the performance of conventional immunoassay methods. Q-body is a single-chain variable region (scFv) or antigen-binding fragment (Fab) that combines an antibody's heavy chain variable region (VH) and light chain variable region (VL), along with a linker.
The organisation plans to use the January 2023 funding for recruitment, research, and development.
Current Investors
Jigyo Souzou Capital, Coral Capital, UT Founder's Association
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.hikariq.co.jp
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.